Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21051305 | 1.00 | ACACB (0.42) | ACACBSLC5A2SLC5A1HRH3CHEK1 | |
| SCHEMBL21051334 | 1.00 | ACACB (0.42) | ACACBSLC5A2SLC5A1HRH3CHEK1 | |
| SCHEMBL19166246 | 0.95 | CHEK1 (0.43) | ACACBSLC5A2SLC5A1HRH3CHEK1 | |
| SCHEMBL28644458 | 0.89 | ACACB (0.46) | ACACBHRH3CHEK1 | |
| SCHEMBL14603517 | 0.89 | LIPG (0.45) | ACACBHRH3LIPG | |
| SCHEMBL21051593 | 0.84 | ESR2 (0.42) | ACACB | |
| SCHEMBL2230216 | 0.83 | AKT1 (0.40) | ACACBSLC5A2SLC5A1HRH3IRAK4 | |
| SCHEMBL744274 | 0.83 | AKT1 (0.40) | ACACBSLC5A2SLC5A1HRH3IRAK4 | |
| SCHEMBL2226844 | 0.83 | AKT1 (0.40) | ACACBSLC5A2SLC5A1HRH3IRAK4 | |
| SCHEMBL21443397 | 0.81 | LRRK2 (0.43) | ACACBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| CN-117321036-A | phenyl-O-quinoline, quinazoline, thienopyridine, thienopyrimidine, pyrrolopyridine, pyrrolopyrimidine compounds having anticancer activity | 成都安泰康赛生物科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2023244788-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20190177327-A1 | SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190177327-A1 | SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2019-06-13 | — | — | US | disclosed |
| US-8097637-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097637-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2185513-B1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| EP-2185513-B1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| EP-2185513-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009019174-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009019174-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | WO | disclosed |
| US-20090042943-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN-LA ROCHE, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042943-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN-LA ROCHE, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042943-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN-LA ROCHE, INC. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042943-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR5A | ACACB 4815/4885SLC5A2 2721/4885SLC5A1 2595/4885 |
| US-20190177327-A1 | SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS | PDE3A, PDE5A, PDE4A | ACACB 4336/4885SLC5A2 3698/4885SLC5A1 1861/4885 |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | ACACB 3491/4885SLC5A2 4615/4885SLC5A1 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.